<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074826</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-AFIB-REG</org_study_id>
    <nct_id>NCT02074826</nct_id>
  </id_info>
  <brief_title>Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation</brief_title>
  <acronym>LOGICAL</acronym>
  <official_title>Analysis of the Interplay Between Genetic Risk Variants for Atrial Fibrillation and Pathological Changes That Associate With the Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universit채t Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-centre cohort study aims to investigate the association between
      known genetic Atrial Fibrillation (AF) risk variants and the amount of left atrial fibrosis
      found in patients undergoing clinically indicated AF catheter ablation procedures.

      Left atrial fibrosis is increasingly recognized as a fundamental part of the
      pathomorphological substrate creating an electrophysiological environment needed for
      electrical conduction heterogeneities. Such identification and treatment of left atrial
      fibrosis has already entered routine clinical use for RF catheter ablation in an attempt to
      develop an individualized and tailored treatment strategy. Today, it is unclear what impacts
      the development, the extent and the localization of left atrial fibrosis in different
      patients.

      A number of genetic risk variants have been described that confer risk of AF and have been
      widely replicated. This indicates that genetic variants contribute to the risk of the
      individual to develop AF throughout his life. However, the mechanisms of how genetic variant
      impact the development of clinical arrhythmias is not yet well understood.

      We hypothesize that genetic influences that lead to tissue changes may play a role in the
      development of the arrhythmia substrate for AF. This is likely to be especially true for
      those with a relatively brief history of AF and modest clinical disease burden. Therefore, we
      plan to investigate the association between known genetic AF variants and a detailed disease
      phenotype obtained from individual left atrial voltage mapping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient is referred for a radiofrequency (RF) ablation procedure for AF on clinical
      indications. All patients undergoing this procedure and fulfilling the inclusion criteria and
      not having any exclusion criteria are invited to participate in the study. After written
      informed consent, a patient is subjected to the study protocol of AF ablation. Detailed
      clinical information is obtained in addition to all data from imaging studies.

      For genetic testing blood samples in EDTA (ethylenediaminetetraacetic) vacutainers will be
      collected from the study participants that will be performed at deCODE genetics in Reykjavik,
      Iceland. Samples will be frozen at -20째C and shipped to deCODE (deCODE genetics, Sturlugata
      8, IS-101 Reykjavik, Iceland) in batches on ice. All sample handling, DNA isolation, and
      genotyping at deCODE will be performed in Clinical Laboratory Improvement Amendments (CLIA)
      and College of American Pathologists (CAP) accredited laboratories. The blood samples
      collected will be labelled using stickers with encrypted identifiers provided by deCODE. The
      key linking encrypted identifiers and the patient names will be stored in a secure location
      by the primary investigator in Dresden, Germany. The clinical data sent to deCODE will be
      encrypted in the same manner. Neither participants or third parties (e.g. health care
      insurance companies) will have any access to the genetic information collected.

      Genotyping of the AF associated variants: DNA will be isolated in deCODE's CLIA and CAP
      accredited diagnostics laboratory from blood samples using the Chemagen method (Perkin
      Elmer). The SNPs (single nucleotide polymorphism) outlined in Table 1 will be genotyped using
      the Centaurus (Epoch Biosciences) platform. The genotyping of these markers have been
      analytically validated at deCODE using a comprehensive validated LIMS (Laboratory Information
      Management System) system that tracks every step in the process from registration to the
      final test report. Genotyping results for study participants will be stored in deCODE
      database under encrypted identifiers.

      Prior to the ablation procedure, transesophageal echocardiography will be performed to
      exclude thrombus formation within the LA (left atrium). Electrophysiological studies are
      going to be performed in the post-absorptive state under deep sedation using midazolam and
      propofol. All antiarrhythmic medications will be discontinued at least five half-lives before
      the study, except amiodarone. Conventional 12-lead surface ECG (filtered 0.05-100 Hz) and
      bipolar intracardiac electrogram recordings (filtered 30-500 Hz) are amplified and displayed
      on Bard Laboratory System, (Bard Electrophysiology, Billerica, MA). A quadripolar and a
      decapolar catheter are introduced via the left femoral vein into the right ventricular apex
      and coronary sinus (CS) with a proximal pole at the CS ostium respectively. If atrial
      fibrillation (AF) is present in the beginning, a electric cardioversion (up to 3 times) will
      be performed to obtain sinus rhythm (SR).

      A single transseptal puncture under fluoroscopic guidance will provide access into the LA.
      Repeated doses of heparin will be used to maintain an activated clotting time of 250 to 350
      seconds throughout the whole procedure.

      Mapping and ablation procedures will be guided by a 3D electroanatomical mapping system
      (CARTO 3, Biosense Webster, Inc., Diamond Bar, CA, USA or Ensite-Velocity, Endocardial
      Solutions, Inc., St. Paul, Minnesota, USA) in all patients. To quantify the amount of left
      atrial fibrosis, a bipolar voltage map will be carried out simultaneously during the CT-based
      3D reconstruction of left atrium. All points will be taken in sinus rhythm. Radiofrequency
      alternating current will be delivered in a unipolar mode between the irrigated-tip electrode
      of the ablation catheter (Surround Flow, Biosense Webster or IBI Therapy CoolFlex, St. Jude
      Medical) and an external back plate electrode. The standard ablation settings include a
      preselected power of 40 W, and a flow rate of 15 or 17 ml/min (15 ml/min for Surround Flow,
      and 17 ml/min for CoolFlex). A temperature probe in the esophagus at the level of the LA is
      used to tag the esophageal location and to provide intraesophageal temperature feedback
      during the procedure. For the ablation procedure a ablation protocol is completed.

      The following procedure data is recorded:

        -  Procedure date

        -  Initial rhythm: sinus rhythm, atrial fibrillation, atrial tachycardia

        -  Procedure time

        -  Fluoroscopy time and dose

        -  Ablation duration

        -  Ablation energy

        -  Isolation of each pulmonary vein

        -  Adverse events / procedure-related events: tamponade, stroke, myocardial infarction,
           pulmonary embolism, pulmonary edema

      The primary end point is reached when a detailed endocardial voltage mapping has been
      performed and correlated with the suggested genetic AF markers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Association between the suggested genetic AF risk variants and the amount of left atrial low voltage zones</measure>
    <time_frame>baseline</time_frame>
    <description>The primary endpoint of the study measures the association between the suggested genetic AF risk variants and the amount of left atrial fibrosis found on detailed endocardial voltage mapping.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy exposure</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural ablation duration</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from recurrences of AF or MRT (magnetic resonance tomography) after substrate guided AF ablation during follow up</measure>
    <time_frame>6 and 12 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the proposed genetic markers and the patients clinical characteristics</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the proposed genetic markers and short and long term ablation success</measure>
    <time_frame>6 and 12 months afte inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the proposed genetic markers and hard clinical outcome parameters</measure>
    <time_frame>6 and 12 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>Genotyping of the AF associated variants
Measurement of the amount of left atrial fibrosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples in EDTA plastic vaccutainers will be collected from the study participants for
      genetic testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from our primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented atrial fibrillation in 12-lead ECG

          -  Paroxysmal or persistent symptomatic atrial fibrillation

          -  Ineffectiveness of antiarrhythmic medication (at least 1 medication) or indication for
             primary AF ablation according to current guidelines

          -  Age 18-75 years

        Exclusion Criteria:

          -  Reversible etiology of atrial fibrillation

          -  Pregnancy

          -  Women of childbearing potential without a negative pregnancy test within 48 hours
             prior to the ablation procedure

          -  Known intracardiac or other thrombi

          -  Contraindication to anticoagulation

          -  Previous left atrial ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Piorkowski, PD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Electrophysiology, University of Dresden - Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David O. Arnar, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Landspitali University Hospital Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas P Gaspar, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Electrophysiology, University of Dresden - Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Forkmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Electrophysiology, University of Dresden - Heart Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias Forkmann, Dr. med.</last_name>
    <phone>+ 49 351 450 1901</phone>
    <email>mathias.forkmann@mailbox.tu-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Huo, Dr. med.</last_name>
    <phone>+ 49 351 450 1901</phone>
    <email>dr.huoyan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Dresden, Depart. of Electrophysiology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Forkmann, Dr. med.</last_name>
      <phone>+ 49 351 450 1901</phone>
      <email>mathias.forkmann@mailbox.tu-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Yan Huo, Dr. med.</last_name>
      <phone>+ 49 351 450 1901</phone>
      <email>dr.huoyan@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Piorkowski, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universit채t Dresden</investigator_affiliation>
    <investigator_full_name>Mathias Forkmann</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

